Back to headlines
Binding Site appoints new Chief Executive Officer
8th December 2010
Birmingham, UK – 8 December 2010. The Binding Site Corporation Limited (“Binding Site” or “the Company”), a privately-owned specialist U.K. diagnostics company, today announces the appointment of Charles de Rohan as Chief Executive Officer.
Charles de Rohan has worked in the diagnostic industry for more than 17 years and brings significant experience to the Company. He was previously CEO of London-quoted Genetix Group, a highly profitable and fast-growing cell imaging and analysis company with revenues exceeding $50m. By moving Genetix’s strategic focus from products to customers, he broadened its offering through the introduction of new tools and processes and the identification of complementary acquisitions. In 2009 he successfully negotiated the takeover of Genetix by Danaher Corporation, where it forms part of Leica Microsystems.
Prior to joining Genetix, Charles spent 15 years at Abbott Laboratories' Diagnostic Division, where he held a number of senior commercial management positions in Europe and Asia Pacific. From November 2003 he was Divisional Vice President in Commercial Operations, managing various European operations. In December 2006 he established a new role as Divisional Vice President, Scientific Leadership and Global Accounts EMEA, where he was responsible for pursuing potential new business models for the core laboratory business as well as developing and executing a strategy to differentiate the company’s offering through its science.
Charles began his career in 1984 at Ernst and Young, where he trained as a chartered accountant, working in a number of positions including forensic accounting, before moving into the management consultancy side of the business.
Prof. Jo Bradwell, the founder and Chairman of The Binding Site, said, “Charles brings a wealth of international and operational expertise and his experience in driving dynamic, high growth businesses will be invaluable as we meet the challenge of the next phase of our development. This is an exciting period for The Binding Site as our leading product Freelite® continues to develop its international footprint and we continue to work on developing new products and entering new markets.”
Charles de Rohan commented, “I am very impressed by the quality and ambition of the team at The Binding Site and the extraordinary achievements to date. Early detection is critical for improved treatment and diagnostics are becoming increasingly important to the pharmaceutical industry as they develop the next generation of therapeutics. The Binding Site has a strong and growing portfolio of products and I look forward to working with the team to further expand the prospects for the business.”